Dako Denmark A/S v. Leica Biosystems Melbourne Party Ltd.

662 F. App'x 990
Court of Appeals for the Federal Circuit·Decided December 2, 2016·No. 2015-1997; 2016-1000·Unpublished

Opinion

Prost, Chief Judge.

These appeals arise from two inter partes reexaminations that invalidated the challenged claims of U.S. Patent No. 7,217,392 (“’392 patent”) and a continuation of that patent, U.S. Patent No. 7,553,672 (“’672 patent”). In those reexaminations, the United States Patent and Trademark Office, Patent Trial and Appeal Board (“Board”) determined that the claims of the ’392 patent are invalid as obvious under 35 U.S.C. § 103 and that the claims of the ’672 patent are invalid as anticipated under 35 U.S.C. § 102 and obvious under 35 U.S.C. § 103. On appeal, Dako Denmark A/S (“Dako”) challenges the Board’s determinations with respect to claim 7 of the ’392 patent and claim 2 of the ’672 patent. For the reasons discussed below, we affirm.

Background

I

Dako is the assignee of both the ’392 patent and the ’672 patent. On May 3, 2011, Leica Biosystems Melbourne Party Ltd. (“Leica”) filed a request for inter partes reexamination of the ’392 patent. Shortly thereafter, Leica filed a second request regarding the ’392 patent. The Board granted both requests and subsequently merged the reexaminations. Upon reexamination, the patent examiner rejected all the issued claims of the ’392 patent. Dako only appealed the examiner’s rejection of independent claim 7 to the Board. On appeal, the Board affirmed the examiner’s rejection, concluding that the claim was obvious based on the combination of two prior art references—U.S. Patent No. 5,439,649 (“Tseung”), and U.S. Patent No. 5,273,905 (“Muller”).

On June 29, 2011, Leica requested inter partes reexamination of the ’672 patent. After reexamination, the examiner rejected four of the issued claims. Dako only appealed the rejection of dependent claim 2 to the Board. On appeal, the Board affirmed the examiner’s rejection, concluding that the claim was both anticipated by Tseung and obvious based on Tseung.

Dako now appeals the Board’s decisions. We have jurisdiction under 28 U.S.C. § 1295(a)(4)(A).

We address each patent in turn.

II

The ’392 patent relates to slide staining devices “for the application and removal of reagents to biologic tissue sections mounted on microscope slides.” ’392 patent col. 2 11. 7-9. Slide staining is a tool used to aid in the microscopic examination of tissue samples. Id. at col. 111. 17-19. In preparation for examination, tissue sections are thinly sliced before being placed on a microscope slide, and are “nearly transparent” if untreated. Id. at col. 111. 19-21. In order to visualize various features of the samples, different techniques are applied which have the effect of coloring, or staining, the sample. Id. at col. 1 11. 20-29. Because different staining techniques “require[ ] the addition and removal of reag *993 ents in a defined sequence for specific time periods, at defined temperatures[,] ... a need arises for a slide stainer that can perform a diversity of stains simultaneously under computer control, as specified by the technologist.” Id. at col. 1 11. 29-35.

In addition to the need for a slide stainer that can apply different processes to a single slide, the specification identifies a further need for a slide stainer that is able to simultaneously process multiple slides in different ways. See id. at col. 2 11. 7-16. As different staining techniques potentially require that slides be heated at different temperatures, and for different times, the ’392 patent describes slide staining systems and methods that “allow[ ] for the heating of each slide to its own specified temperature.” Id. at col 211.13-18.'

In order to facilitate this individualized control, the patent describes a system containing multiple “slide frames” in which each slide frame contains a separate heating element. Id. at col. 4 11. 4-11. Figure 5, shown below, illustrates one embodiment of a slide frame and, “is a top view of the slide frame base with five microscope slides in their appropriate positions, showing the area to which heat is applied.” Id. at col. 311.17-20.

[[Image here]]

Id. at fig.5.

Claim 7 of the ’392 patent, which the Board found obvious, reads:

7. A microscope slide stainer, comprising:
a staining protocol program comprising instructions for applying reagents and heat to a plurality of microscope slides bearing biological samples;
a plurality of slide supports, each support being comprised of a heating ele- *994 ment that underlies only one microscope slide and having a surface on which only one microscope slide rests so as to transfer heat to the one microscope slide;
at least one reagent dispenser that can dispense a liquid reagent onto a microscope slide on one of the slide supports;
a movable carriage that causes the reagent dispenser to be aligned over a desired microscope slide on one of the slide supports, as specified in the slide staining program, so that reagent dispensed out of the reagent. dispenser drops onto an underlying microscope slide on one of the slide supports; and
a control system that issues commands to cause relative motion between the reagent dispenser and the microscope slide on one of the slide supports so that the reagent dispenser is aligned over the'microscope slide on one of the slide supports, as specified in the staining protocol program, and that issues commands to cause the heating elements to heat at the times specified in the staining protocol program, the control system controlling heating of one heating element to a different temperature as another,

’392 patent col. 13 1.14-col. 14 1. 3 (emphasis added).

In its analysis, the Board first determined that Tseung, a prior art reference, disclosed every claim limitation except the requirement that each' heating element underlies only one microscope slide. To supply this limitation, the Board looked to Muller, a second prior art reference, which disclosed individual heating elements for each slide. The Board also determined that there was a motivation to combine Tseung with Muller because Muller’s teachings were “directly pertinent to Tseung.” No. 15-1997 J.A. 15, The Board explained that both references used heating in their automated staining devices and that this provided a reason to combine the references.

In finding a motivation to combine, the Board addressed, and rejected, four arguments Dako made that were supported only by testimony from Dr. Floyd, its expert, and Dr. Bogen, one of the named inventors of the ’392 patent.

Free access — add to your briefcase to read the full text and ask questions with AI

Dako Denmark A/S v. Leica Biosystems Melbourne Party Ltd., 662 F. App'x 990 (Fed. Cir. 2016).

662 F. App'x 990 (Dako Denmark A/S v. Leica Biosystems Melbourne Party Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Graham v. John Deere Co. of Kansas City
383 U.S. 1 (Supreme Court, 1966)
KSR International Co. v. Teleflex Inc.
550 U.S. 398 (Supreme Court, 2007)
In Re NTP, Inc.
654 F.3d 1268 (Federal Circuit, 2011)
In Re Robert J. Gartside and Richard C. Norton
203 F.3d 1305 (Federal Circuit, 2000)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
Star Scientific, Inc. v. R.J. Reynolds Tobacco Co.
655 F.3d 1364 (Federal Circuit, 2011)
Inre: Rambus, Inc.
753 F.3d 1253 (Federal Circuit, 2014)
Microsoft Corporation v. Proxyconn, Inc.
789 F.3d 1292 (Federal Circuit, 2015)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)